遺伝子工学の進歩
オープンアクセス

概要

Bench to Bed - Molecular for COVID-19 Investigation

Syed Faizan Raza

First isolated in China in early 2020, Severe Acute RespiratorySyndrome Coronavirus-2 (SARS-CoV-2) is the novel coronavirusresponsible for the ongoing pandemic of CoronavirusDisease 2019 (COVID-19). The disease has been spreading rapidly across the globe, with the largest burden falling on China,Europe, and the United States. COVID-19 is a new clinical syndrome, characterized by respiratory symptoms with varying degrees of severity, from mild upper respiratory illness to severe interstitial pneumonia and acute respiratory distress syndrome, aggravated by thrombosis in the pulmonary microcirculation.Three main phases of disease progression have been proposed for COVID-19: an early infection phase, a pulmonary phase, and a hyperinflammation phase. Although current understanding of COVID-19 treatment is mainly derived from smalluncontrolled trials that are affected by a number of biases,strong background noise, and a litany of confounding factors,emerging awareness suggests that drugs currently used to treatCOVID-19 (antiviral drugs, antimalarial drugs, immunomodulators, anticoagulants, and antibodies) should be evaluated inrelation to the pathophysiology of disease progression. Drawing up the dramatic experiences taking place in Italy and around the world, here we review the changes in the evolution of the disease and focus on current treatment uncertainties and promising new therapies.